AMA-37

发表于由

上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白，专注于信号通路和疾病研究领域。

AMA-37  纯度: 99.15%

AMA-37 是Arylmorpholine 的类似物，是ATP 竞争性的DNA-PK 抑制剂，其IC50 值分别为0.27 μM (DNA-PK)、32 μM (p110α)、3.7 μM (p110β)、and 22 μM (p110γ)。

AMA-37

AMA-37 Chemical Structure

CAS No. : 404009-46-7

规格 价格 是否有货 数量
5 mg ￥6100 In-stock
10 mg ￥9750 In-stock
50 mg   询价  
100 mg   询价  

* Please select Quantity before adding items.

AMA-37 相关产品

•相关化合物库:

  • Bioactive Compound Library Plus
  • Cell Cycle/DNA Damage Compound Library
  • Kinase Inhibitor Library
  • PI3K/Akt/mTOR Compound Library
  • Anti-Cancer Compound Library
  • Anti-Aging Compound Library
  • Oxygen Sensing Compound Library
  • Glycolysis Compound Library
  • Cytoskeleton Compound Library
  • Anti-Pancreatic Cancer Compound Library
  • Anti-Cancer Metabolism Compound Library
  • Glucose Metabolism Compound Library

生物活性

AMA-37, an Arylmorpholine analog, is ATP-competitive DNA-PK inhibitor, with IC50 values of 0.27 μM (DNA-PK), 32 μM (p110α), 3.7 μM (p110β), and 22 μM (p110γ), respectively[1][2].

IC50 & Target

IC50: 0.27 μM (DNA-PK)[1].
体外研究
(In Vitro)

AMA-37 inhbits PI3K poorly[2].
AMA-37 (20 μM) reduces the ability of UCN-01, isogranulatimide, and debromohymenialdesine, but not caffeine, to overcome G2 arrest (ρ < 0.05)[3].
Inhibition of DNA-PK with AMA37 leads to radiosensitization[3].

Shanghai Jinpan Biotech Co Ltd has not independently confirmed the accuracy of these methods. They are for reference only.
分子量

283.32

Formula

C17H17NO3
CAS 号

404009-46-7
运输条件

Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
参考文献

  • [1]. Zachary A Knight, et al. A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell. 2006 May 19;125(4):733-47.

    [2]. Zachary A Knight, et al. Isoform-specific phosphoinositide 3-kinase inhibitors from an arylmorpholine scaffold. Bioorg Med Chem. 2004 Sep 1;12(17):4749-59.

    [3]. Christopher M Sturgeon, et al. Effect of combined DNA repair inhibition and G2 checkpoint inhibition on cell cycle progression after DNA damage. Mol Cancer Ther. 2006 Apr;5(4):885-92.

所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务